Spelling suggestions: "subject:"thrombose 1""
21 |
Efeitos do LDL oxidado em macrófagos M2. Implicações na aterosclerose. / Effects of oxidized LDL in M2 macrophages. Implications in atherosclerosisFernanda Magalhães Gonçalves 12 September 2017 (has links)
A aterosclerose é uma doença crônica onde duas características marcantes são observadas: retenção de lipídios e inflamação. Compreender as interações entre as células do sistema imunológico e as lipoproteínas envolvidas na aterogênese são desafios urgentes, uma vez que as doenças cardiovasculares são a principal causa de morte no mundo. Os macrófagos são cruciais para o desenvolvimento de placas ateroscleróticas e para a perpetuação da inflamação em tais lesões; estas células também estão diretamente envolvidas na ruptura de placa instável. Recentemente diferentes populações de macrófagos estão sendo identificadas nas lesões ateroscleróticas. Embora macrófagos M2 tenham sido identificados, a função destas células na aterosclerose ainda não está definida. Neste projeto, avaliamos se a adição de LDLox altera a função de macrófagos M2. Resultados: 1- Foi possível observar que os M2 se mantem viáveis após o estímulo com as lipoproteínas. 2- Quando avaliamos a expressão de moléculas co-estimulatórias, receptores Scavenger, lectinas e integrinas na superfície das células, observamos que a adição de LDLn ou LDLox em 2 concentrações diferentes (5 e 50ug/ml), por diferentes períodos de tempo não alterou a expressão de nenhum dos marcadores avaliados. A presença de LDL também não alterou outra função primordial dos M2, a capacidade de fagocitose. 3- Quando investigamos a presença de citocinas no sobrenadante das culturas estimuladas ou não com as lipoproteínas, identificamos um aumento na secreção de IL-8, uma citocina pró-inflamatória, na presença de LDLox, semelhante ao observado com a população de macrófagos M1. 4- Avaliamos se os macrófagos M2 estimulados ou não com LDL mantem sua capacidade de favorecer a angiogênese. Observamos que nas culturas estimuladas com o sobrenadante das culturas dos M2 mantidos na presença de LDLox houve uma inibição significativa da formação de túbulos pelas HUVECs. 5- Observamos que na presença do meio condicionado dos M2 estimulados com LDLox ocorreu uma intensa degradação dos filamentos de matriz extracelular produzida por MEFs. 6- Avaliamos a expressão gênica de componentes de matriz, membrana basal, moléculas de adesão, proteases e também inibidores de protease nestas células. Dos 96 genes avaliados, observamos que a adição de LDLox reduziu a expressão de 10 genes de maneira significativa, entre eles: beta-Actina (ACTB), Colágeno 6A2 (Col6A2), Integrina alfa 6 (ITGA6), Metaloproteinase 15 (MMP15), molécula de adesão celular endotelial plaquetária (PECAM) e Inibidor de metalopeptidase 2 (TIMP2). A adição de LDLox aumentou significativamente somente a expressão de trombospondina (TSP1). A adição de LDLn não alterou a expressão de nenhum gene de forma significativa. 7- A adição de LDLox induziu aumento da expressão da TSP1 e redução da expressão de colágeno 6, quando comparadas aos macrófagos M2 sem estímulo. Nossos resultados indicam que a adição de LDLox altera diversas funções dos macrófagos M2 in vitro. Em especial detectamos uma inibição significativa na angiogênese e também a secreção de mediadores que induzem a degradação da matriz extracelular. A adição de LDLox também inibiu a expressão de genes envolvidos com a estabilização da matriz extracelular. Nossos resultados sugerem que esta população de células pode contribuir para a perpetuação do processo inflamatório e degradação tecidual observados na lesão dos pacientes. Assim, acreditamos que este projeto contribuiu para o esclarecimento da participação dos M2 na patologia da aterosclerose / Atherosclerosis is a chronic disease where two key characteristics are observed: lipid retention and inflammation. Understanding the interactions between the cells of the immune system and the lipoproteins involved in atherogenesis are urgent challenges, since cardiovascular diseases are the leading cause of death in the world. Macrophages are crucial for the development of atherosclerotic plaques and for the inflammation in such lesions; These cells are also directly involved in unstable plaque rupture. Recently different populations of macrophages are being identified in atherosclerotic lesions. Although M2 macrophages has been identified, the function of these cells in atherosclerosis has not yet been defined. This project, we evaluated whether the addition of OxLDL alters the function of M2 macrophages. Results: 1- M2 macrophages remain viable after stimulation with the lipoproteins. 2- When evaluated the expression of co-stimulatory molecules, Scavenger receptors, lectins and integrins on the surface of the cells. We observed that the addition of LDLn or OxLDL at 2 different concentrations (5 and 50 ?g / ml) for different time periods did not alter the expression of any of the evaluated markers. 3- The presence of LDL also did not alter other primordial function of M2 cells, phagocytosis. 4- Was observed that cultures stimulated with conditioned medium of OxLDL-stimulated M2 there was a significant inhibition of tubule formation by HUVECs. 5- We observed that in the presence of OxLDL-stimulated M2 cells conditioned médium an intense degradation of the matrix filaments occurred. 6- We evaluated the gene expression of matrix components, basement membrane, adhesion molecules, proteases and also protease inhibitors in these cells. Of the 96 evaluated genes, we observed that the addition of OxLDL significantly reduced the expression of 10 genes, among them: Actin-beta (ACTB), Collagen 6A2 (Col6A2), Integrin alfa 6 (ITGA6), Metaloproteinase 15 (MMP15), Platelet endothelial cell adhesion molecule (PECAM) and metallopeptidase 2 inhibitor (TIMP2). The addition of OxLDL significantly increased only the expression, thrombospondin-1 (TSP1). Addition of LDLn did not significantly alter the expression of any gene. 7- That OxLDL addition induced increased TSP1 expression and reduced collagen 6 expression, when compared to M2 macrophages without stimulation. Our results indicate that the addition of OxLDL alters several M2 macrophages functions in vitro. In particular we detected a significant inhibition in angiogenesis and also the secretion of mediators that induce the degradation of the extracellular matrix. The addition of OxLDL also inhibited the expression of genes involved in extracellular matrix stabilization. Our results suggest that this cell population may contribute to the perpetuation of the inflammatory process and tissue degradation observed in the lesion of the patients. Thus, we believe that this project contributed to better understand the participation of M2 in the pathology of atherosclerosis
|
22 |
Étude d'un inhibiteur de la protéine anti-angiogénique thrombospondine-1 comme traitement de la prééclampsie chez la sourisMarc, Casandra 09 1900 (has links)
Introduction : La prééclampsie (PE) est un trouble hypertensif caractérisé par une tension artérielle au-dessus de 140/90 mmHg et touche 2 à 8% des grossesses globalement. À ce jour, la plupart des médicaments ne peuvent traiter ou prévenir la PE. La thrombospondine-1 (THBS1) est un facteur anti-angiogénique et un activateur principal du TGF-β, ce qui pourrait également être impliqué dans l'altération de l'angiogenèse dans les placentas prééclamptiques.
Objectif : Notre objectif est de décrire l'expression de la THBS1 et de tester l’effet d’un inhibiteur, le peptide LSKL, sur la vascularisation placentaire dans les placentas d'un modèle murin de PE (in vivo) et sur la capacité angiogénique des cellules endothéliales placentaires humaines (in vitro).
Méthodes : L'expression de THBS1 a été mesurée dans les placentas de souris par western blot et dans les placentas humains par immunohistochimie (IHC). Des cellules endothéliales placentaires (pECs) extraites de placentas humains et des souris enceintes hétérozygotes femelles surexprimant la rénine et l’angiotensinogène humaines (hR+A+) sont traitées avec LSKL, ou son peptide témoin SLLK (cellules : 30 μmol/L pendant24h ; animal 129 μmol/mL s.c. au jour de gestation 14,5). Des pEC ont été soumises à des conditions contrôle (8% d’oxygène) ou hypoxie (0,5% d’oxygène) ou thrombine (10 unités/mL) pendant 24 h. L’angiogenèse cellulaire a été évaluée sur matrigel, les protéines évaluées par western blot et la localisation de la THBS1 ainsi que la vascularisation placentaire par IHC.
Résultats : Le traitement avec LSKL augmente le nombre de tubes formées dans les pECs exposées à la thrombine ou à l’hypoxie. L’inhibiteur de la voie canonique du TGF-β, ALK5/Smad2/3 (SB-505124, SB), n’a pas modifié la capacité de formation de tubes, contrairement à l’inhibiteur de la voie non canonique, TAK1/p38 ((5Z) -7-oxozeaenol, (OXO) qui a réduit la capacité angiogénique (p<0,05). Chez le modèle de souris de PE, LSKL a significativement amélioré la vascularisation placentaire, évaluée par le contenu des cellules endothéliales CD31+ marquées par IHC (p<0,05), qui s’est accompagnée d’une phosphorylation réduite de TAK1 et ERK dans ce tissu.
Conclusion : Nos résultats indiquent une augmentation de l’expression de la THBS1 dans les vaisseaux et cellules endothéliales placentaires des grossesses atteintes de PE, ainsi qu’un effet pro-angiogénique placentaire du LSKL par inhibition de la vie non-canonique du TGF-β. Ces résultats contribueront à identifier de nouvelles cibles thérapeutiques capables d'améliorer la vascularisation placentaire dans PE. / Introduction: Pre-eclampsia (PE) is a hypertensive disorder characterized by blood pressure above 140/90 mmHg and affects 2% to 8% of pregnancies globally. To date, most drugs cannot treat or prevent PE. Thrombospondin-1 (THBS1) is an anti-angiogenic factor and a major activator of TGF-β, which may also be involved in impaired angiogenesis in pre-eclamptic placentas.
Objective: Our aim is to describe the expression of THBS1 and to test the effect of its inhibitor, LSKL peptide, on placental vascularization in placentas from a mouse model of PE (in vivo) and on the angiogenic capacity of human placental endothelial cells (in vitro).
Methods: THBS1 expression was measured in placentas of mouse by western blot and in human placentas by immunohistochemistry (IHC). Placental endothelial cells (pECs) extracted from hu-man placentas and pregnant female heterozygous mice overexpressing human renin and angio-tensinogen (hR+A+) were treated with LSKL or its control peptide SLLK (cells: 30 μmol/L for 24h; animals: 129 μmol/mL subcutaneously on gestation day 14.5). pECs were subjected to control conditions (8% oxygen) or hypoxia (0.5% oxygen) or thrombin (10 units/mL) for 24 hours. Cellular angiogenesis was assessed on Matrigel, proteins were evaluated by western blot, and the locali-zation of THBS1 as well as placental vascularization were examined by immunohistochemistry (IHC).
Results: Treatment with LSKL increased the number of tubes formed in pECs exposed to thrombin or hypoxia. The inhibitor of the canonical TGF-β pathway, ALK5/Smad2/3 (SB-505124, SB), did not alter tube formation capacity, unlike the inhibitor of the non-canonical pathway, TAK1/p38 ((5Z)-7-oxozeaenol, (OXO)), which reduced angiogenic capacity. In the mouse model of PE, LSKL significantly improved placental vascularization, assessed by CD31+ endothelial cell content marked by IHC, which was accompanied by reduced phosphorylation of TAK1 and ERK in this tissue.
Conclusion: Our results indicate an increase in THBS1 expression in the vessels and placental endothelial cells of pregnancies affected by PE, as well as a pro-angiogenic effect of LSKL through the inhibition of the non-canonical TGF-β pathway. These findings contribute to identifying new therapeutic targets capable of improving placental vascularization in PE.
|
23 |
Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascadeRoberts, Wayne, Magwenzi, S., Aburima, Ahmed, Naseem, Khalid M. January 2010 (has links)
No / Cyclic adenosine monophosphate (cAMP)-dependent signaling modulates platelet function at sites of vascular injury. Here we show that thrombospondin-1 (TSP-1) prevents cAMP/protein kinase A (PKA) signaling through a CD36-dependent mechanism. Prostaglandin E(1) (PGE(1)) induced a robust inhibition of both platelet aggregation and platelet arrest under physiologic conditions of flow. Exogenous TSP-1 reduced significantly PGE(1)-mediated inhibition of both platelet aggregation and platelet arrest. TSP-1 prevented PGE(1)-stimulated cAMP accrual and phosphorylation of PKA substrates, through a mechanism requiring phosphodiesterase3A. TSP-1 also inhibited VASP phosphorylation stimulated by the nonhydrolyzable cAMP analog, 8-bromo-cAMP, indicating that it may regulate cAMP-mediated activation of PKA. The inhibitory effect of TSP-1 on cAMP signaling could be reproduced with a peptide possessing a CD36 binding sequence of TSP-1, while the effects of TSP-1 were prevented by a CD36 blocking antibody. TSP-1 and the CD36 binding peptide induced phosphorylation of Src kinases, p38 and JNK. Moreover, inhibition of Src kinases blocked TSP-1-mediated regulation of cAMP concentrations and the phosphorylation of VASP, indicating that TSP-1 modulated the cAMP/PKA signaling events through a tyrosine kinase-dependent pathway downstream of CD36. These data reveal a new role for TSP-1 in promoting platelet aggregation through modulation of the cAMP-PKA signaling pathway.
|
Page generated in 0.0636 seconds